<DOC>
	<DOCNO>NCT02052128</DOCNO>
	<brief_summary>This multi-center , open-label , randomize , parallel group two-stage phase 1 study phase 2 expansion component pt recurrent metastatic APRpos uterine endometrioid adenocarcinoma . Stage 1 : Six dose cohort , 5 use extend release tablet ( ER ) formulation ( 10 mg BID , 20 mg BID , 30 mg BID , 40 mg BID , 50 mg BID ) 1 use immediate-release ( IR ) tablet formulation 100 mg QD randomize parallel . After enrollment 36 patient Stage 1 , dose 50 mg BID determine RP2D . Stage 2 : An additional 10 patient recurrent metastatic APRpos uterine endometrioid adenocarcinoma ( Stage 2a ) enrol RP2D . Based response Stage 2a , cohort expand 19 patient total 29 patient confirm efficacy safety profile onapristone select patient population ( Stage 2b ) .</brief_summary>
	<brief_title>Phase 1-2 Study Onapristone Patients With Progesterone Receptor Expressing Cancers</brief_title>
	<detailed_description />
	<mesh_term>Progesterone</mesh_term>
	<mesh_term>Onapristone</mesh_term>
	<criteria>1 . Post menopausal female patient , 18 year age great . 2 . In Stage 1 , recurrent metastatic PRexpressing cancer potential benefit antiprogestin treatment include limited endometrial cancer , ovarian , breast cancer uterine sarcoma . In Stage 2 , recurrent metastatic PRexpression uterine endometrioid adenocarcinoma determine APRpos . 3 . Patients metastatic recurrent disease previous surgery , radiation therapy , and/or chemotherapy eligible . In Stage 1 , restriction place number prior therapy . In Stage 2 , patient may 0 1 prior chemotherapy treatment adjuvant metastatic disease prior endocrine therapy . 4 . In Stage 1 , evaluable disease per RECIST 1.1 . In Stage 2 , measurable disease . 5 . Appropriate archival OR current tissue block biopsy specimen determine ER/PR APR status . 6 . Signed , write informed consent must obtain document accord ICHGCP , local regulatory requirement , local data protection law prior studyspecific screen procedure . 7 . ECOG performance status 01 . 8 . Health care coverage . 1 . Calculated creatinine clearance &lt; 60 mL/min Stage 1 &lt; 40 mL/min Stage 2 2 . Patients prior malignancy allow except follow : Adequately treat basal cell squamous cell skin cancer In situ cervical cancer Adequately treat Stage I II cancer patient currently complete remission cancer patient diseasefree 2 year 3 . Body mass index ( BMI ) &lt; 18.5 &gt; 35 kg/m2 . 4 . On ECG QTc ( F ) interval &gt; 480 msec clinically significant cardiac rhythm abnormality . 5 . Liver function test document within screening period day 1 treatment period : Total bilirubin &gt; ULN ( except patient diagnose Gilbert 's disease ) . Alkaline phosphatase &gt; UNL &gt; 2.5 x UNL case liver metastasis , &gt; 5 x UNL case bone metastasis . ALT/AST &gt; UNL &gt; 2.5 x UNL case liver metastasis . 6 . Known positive virology/serology human immunodeficiency virus ( HIV ) 1 , HIV2 , hepatitis B ( surface antigen ) , hepatitis C. 7 . Chronic inflammatory liver condition . 8 . Chronic adrenal failure receive concurrent longterm corticosteroid therapy . 9 . History clinical evidence surgical medical condition investigator judge likely interfere result study pose additional risk participate . 10 . Used prescription medication prior 1 month investigator judge likely interfere study pose additional risk patient participate . 11 . Received investigational product treat investigational device within 30 day prior first drug administration , plan start investigational product device study within 30 day last drug administration . 12 . Received prior systemic anticancer treatment ( chemotherapy , targeted therapy include kinase inhibitor , antibody , etc ) less 5 halflives first dose study drug radiotherapy within 30 day ; toxicity anticancer treatment must recover grade 1 less . 13 . Current progestinbased hormone replacement therapy . 14 . Lack physical integrity upper gastrointestinal tract , malabsorption syndrome , inability swallow pill . 15 . Has mental incapacity language barrier preclude adequate understanding , cooperation , compliance study requirement . 16 . Is , judgment investigator , unable unwilling comply requirement study . 17 . Uncontrolled brain metastasis treatment neurosurgical resection brain biopsy within 4 week prior Day 1 . 18 . For Stage 2 , mixed histology i.e . patient &gt; 10 % nonendometrioid malignant cell provide histopathology sample .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>endometrial cancer</keyword>
	<keyword>ovarian cancer</keyword>
	<keyword>breast cancer</keyword>
	<keyword>uterine sarcoma</keyword>
	<keyword>uterine endometrioid adenocarcinoma</keyword>
</DOC>